One study showed that NSCLC patients with TP53 missense mutations had significantly shorter PFS treated with first-line EGFR-TKI therapy (HR 1.91, CI 1.01–3.60, P=0.04) (39). Here, EGFR is linked to non-small cell lung carcinoma.